Topical TRPV1 antagonists are well tolerated and are under investigation for the treatment of inflammatory skin diseases, such as atopic dermatitis (PAC-14028, asivatrep; NCT02583022, NCT02757729, and NCT02965118), where they show promising effects.618. The gene discussed is TRPV1; the disease is inflammatory skin disease.